CSF2 and melanoma: Talimogene laherparepvec (T-VEC), based on a genetically modified HSV, which encodes the human granulocyte-macrophage colony-stimulating factor (GM-CSF), is the only one among the seven oncolytic HSVs approved by the FDA and the EMA for the treatment of IIIB/C–IVM1a melanoma.